Purple Biotech Ltd (TLV:PPBT)
Israel · Delayed Price · Currency is ILS · Price in ILA 1.000
0.00 (0.00%)
Jul 27, 2026, 5:24 PM IDT
Purple Biotech Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cost of Revenue | 0.06 | 0.06 | 0.06 | 0.2 | 0.12 | 0.06 |
Gross Profit | -0.06 | -0.06 | -0.06 | -0.2 | -0.12 | -0.06 |
Selling, General & Admin | 3.56 | 3.19 | 3.12 | 5.04 | 6.16 | 6.04 |
Research & Development | 4.2 | 3.73 | 7.62 | 17.03 | 16.32 | 11.83 |
Operating Expenses | 7.76 | 6.92 | 10.74 | 22.08 | 22.48 | 17.87 |
Operating Income | -7.82 | -6.98 | -10.8 | -22.27 | -22.6 | -17.92 |
Interest & Investment Income | 0.2 | 0.23 | 0.26 | 0.47 | 0.53 | 0.32 |
Currency Exchange Gain (Loss) | 0.01 | 0.01 | -0.01 | -0.01 | 0.06 | -0.13 |
Other Non Operating Income (Expenses) | 1.97 | 0.73 | 3.48 | 1.83 | 0.25 | -0.08 |
EBT Excluding Unusual Items | -5.64 | -6.01 | -7.08 | -19.98 | -21.76 | -17.81 |
Asset Writedown | -20.48 | -20.48 | -0.2 | - | - | - |
Legal Settlements | - | - | - | - | - | -0.01 |
Pretax Income | -26.13 | -26.49 | -7.28 | -19.98 | -21.76 | -17.83 |
Earnings From Continuing Operations | -26.13 | -26.49 | -7.28 | -19.98 | -21.76 | -17.83 |
Earnings From Discontinued Operations | - | - | - | - | - | -0.64 |
Net Income to Company | -26.13 | -26.49 | -7.28 | -19.98 | -21.76 | -18.47 |
Minority Interest in Earnings | 0.11 | 0.11 | 0.04 | 0.1 | 0.09 | 0.08 |
Net Income | -26.02 | -26.39 | -7.24 | -19.88 | -21.67 | -18.38 |
Net Income to Common | -26.02 | -26.39 | -7.24 | -19.88 | -21.67 | -18.38 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 1,294 | 960 | 328 | 221 | 181 | 176 |
Shares Outstanding (Diluted) | 1,294 | 960 | 328 | 221 | 181 | 176 |
Shares Change | 230.28% | 192.79% | 48.15% | 22.41% | 2.92% | 52.76% |
EPS (Basic) | -0.02 | -0.03 | -0.02 | -0.09 | -0.12 | -0.10 |
EPS (Diluted) | -0.02 | -0.03 | -0.02 | -0.09 | -0.12 | -0.10 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -6.8 | -5.66 | -14.37 | -19.93 | -16.76 | -15.37 |
Free Cash Flow Per Share | -0.01 | -0.01 | -0.04 | -0.09 | -0.09 | -0.09 |
EBITDA | -7.8 | -6.97 | -10.77 | -22.07 | -22.4 | -17.69 |
D&A For EBITDA | 0.02 | 0 | 0.03 | 0.2 | 0.2 | 0.23 |
EBIT | -7.82 | -6.98 | -10.8 | -22.27 | -22.6 | -17.92 |